Exclusive Meningioma Claimants · MDL 3140 · Since 2009
Depo-Provera Lawsuit Leads & Signed Retainers for Law Firms
Looking for Depo Provera leads? We deliver exclusive, imaging-verified meningioma claimants and signed retainers for plaintiff firms. Pfizer signed the Master Settlement Agreement in July 2026 - but it covers only about 80% of MDL 3140, the docket has kept growing to 6,413 pending actions (November 2026 JPML report), and statutes of limitation are still expiring. Every lead is brand-verified, MRI/CT-confirmed, and screened to your firm's criteria. If a lead doesn't match what you asked for, we replace it free within 7 days.
Here Is a Look at a Sample High Intent Depo-Provera Package
Every qualified claimant arrives as a complete intake summary - case criteria, injury and timeline details, verification, agreements and supporting documents - ready for your intake team to review.
Only available on live transfer and signed retainer lead packages.
Delivery Options
Three Ways to Receive Your Depo Provera Leads
Every docket is different. Choose the stage where you want Depo Provera claimants to land — or mix delivery types as MDL 3140 and the state-court dockets move forward.
Exclusive Web Leads
Pre-screened claimants matched to your Depo Provera criteria — brand, imaging-confirmed diagnosis and injection history — delivered in real time and exclusive to your firm.
- Screened against your written case criteria
- Third-party identity verification before delivery
- Exclusive — never resold, recycled or sold as aged leads
Best for: firms with in-house paralegals or intake staff that want verified Depo Provera volume at scale.
Live Transfers
Our non-incentivized intake agents walk the claimant through your Depo Provera questionnaire by phone, then warm-transfer the call directly to your team.
- Brand use, imaging and statute confirmed before the handoff
- Live conversation while the claimant is engaged
- 100% connect rate — no voicemail, no callback chase
Best for: firms that want a case manager speaking with every Depo Provera claimant first.
Signed Retainers
We handle qualification, documentation and signature on your firm’s retainer — the claimant arrives QC-reviewed with the full file attached.
- Retainer executed on your firm’s paper
- Identity verified, QC-reviewed before delivery
- Minimal intake hours on your side
Best for: firms that want signed claimants on the docket, not leads to chase.
Pricing is quoted per campaign and depends on the litigation stage, your volume and how strict your criteria are.
Want premium Depo-Provera signed retainers for your law firm?One Step Past the Depo Provera Lead
Qualified leads are the middle of what we do, and the rest of this page covers them in detail. If you already know you want something further down the chain — claimants already signed onto your paper — that is a separate service, and you can skip straight to it.
Depo Provera Litigation Status
- 15 June 2026 Global settlement announced in principle. Judge M. Casey Rodgers issued Pretrial Order No. 30A confirming that Plaintiffs' Lead Counsel Christopher Seeger and Pfizer had reached an agreement in principle. Initial bellwether deadlines were vacated.
- 21 July 2026 Pfizer signed the Master Settlement Agreement. The executed agreement resolves most - not all - federal claims in MDL 3140. Allocation terms and individual payment schedules have not been made public.
- 27 July 2026 Causation and preemption hearing held after being reset from the postponed June date.
- 30 July 2026 Three new pilot plaintiffs approved. Judge Rodgers replaced the original five pilot cases, which had become settlement-eligible and could therefore no longer test preemption and general causation. The settlement is reported to cover roughly 80% of pending claims.
- 3 August 2026 6,294 actions pending per the JPML report - up 464 in a single month, making Depo-Provera one of the fastest-growing dockets in the federal MDL system.
- 10 August 2026 Settlement registration deadline set. Case Management Order 14 gives eligible claimants until 30 November 2026 to register. It excludes claims filed too late and claims where the gap between the last injection and the meningioma diagnosis falls outside the required window. The exact cutoffs sit in the confidential agreement.
- 1 September 2026 6,403 actions pending. Filings have continued throughout settlement negotiations, which is the clearest available evidence that firms are still signing and filing Depo-Provera cases.
- 15 September 2026 Preemption motion referred. Judge Rodgers referred Pfizer's preemption motion to Magistrate Judge Hope T. Cannon for a report and recommendation. Pfizer filed a second supplemental brief on 14 October.
- 18 September 2026 Rule 702 general causation hearing held. Judge Rodgers heard argument on whether the plaintiffs' scientific experts may testify. No ruling had been entered as of early November.
- 1 October 2026 6,412 actions pending. Plaintiffs' October status report counted 6,451 complaints filed as of 15 October.
- November 2026 6,413 actions pending, 6,525 filed in total per the November JPML report. Growth has slowed since the summer, but new cases are still being filed.
- 30 November 2026 · Next Milestone Settlement registration closes, and plaintiffs' responses to Pfizer's preemption brief are due. A case management conference follows on 18 December, and settlement payments are expected to begin in the first quarter of 2027.
What this means if you are buying Depo Provera leads. A signed master settlement is not a closed docket. Roughly one case in five inside MDL 3140 falls outside it, claims filed after the settlement cutoff are excluded, and the docket has added cases every month since the June announcement. What has changed is the standard: with allocation criteria unpublished and a Rule 702 ruling pending, a claimant with thin documentation is now a materially weaker asset than one with injection records and imaging in hand. That is the entire basis on which we screen. For the full picture on eligibility, the registration deadline and what falls outside the deal, read our Depo-Provera settlement guide for law firms. See how our mass tort lead generation process handles it, or request current Depo-Provera inventory and pricing.
From Inquiry to Filable File
How Every Depo Provera Lead Is Built
We don't sell raw clicks. As a full-service Depo Provera lead generation partner, each Depo Provera case lead moves through four stages before it reaches your firm - exclusive, compliant, and screened to the imaging-confirmed standard that keeps the case alive.
Criteria Build
We map your docket strategy - surgical vs. monitored meningioma, injection history, target states - into a custom intake script written for your firm.
Targeted Acquisition
National campaigns across medication-specific SEO and paid social reach women with long-term Depo-Provera use. The injection was prescribed everywhere, so coverage is nationwide.
Verification
Lead Insight fraud scanning, live intake-agent screening to your criteria, third-party ID on SSN/address/DOB, and MRI/CT imaging status captured on every file.
Exclusive Delivery
Compliant, CRM-integrated claimant files delivered to your firm only - with questionnaire and required forms attached. Real-time or live transfer to remove lag.
How claimants get qualified
The Science & Theories Driving This Tort
What Makes Depo Provera Leads Viable
The causation foundation in Depo-Provera is among the strongest in pharmaceutical litigation - two peer-reviewed epidemiological studies plus a regulatory action that undercut the defense's central argument. We link the primary sources below rather than paraphrase them, because your case managers should be able to check our screening logic against the actual literature.
| Pillar | What It Establishes |
|---|---|
| BMJ Study (2024) Read the study ↗ |
Roland et al., a French national case-control study of 18,061 women who underwent meningioma surgery, reported an odds ratio of 5.55 (95% CI 2.27–13.56) for intracranial meningioma among women using medroxyprogesterone acetate for more than one year. It remains the core anchor for general causation. |
| JAMA Neurology (Sept 2025) Read the study ↗ |
Xiao et al., a Cleveland Clinic and Case Western analysis of 10,425,438 U.S. women across 68 health systems, found a relative risk of 2.43 (95% CI 1.77–3.33) for meningioma diagnosis. Critically for screening, the elevated risk was concentrated in women with more than four years of exposure or who started after age 31 - and no other contraceptive showed an increase. |
| FDA Label Change (Dec 2025) FDA label database ↗ |
The FDA approved a meningioma warning for U.S. Depo-Provera labels. Pfizer had argued preemption on the basis that the FDA rejected a 2024 label update; the December 2025 approval is widely credited with weakening that defense and driving the filing surge that followed. |
| Rule 702 Hearing Court MDL page ↗ |
Held 18 September 2026 before Judge Rodgers, with a ruling still pending in early November. It decides whether the plaintiffs' general causation experts may testify, and it governs every claim the Master Settlement Agreement does not resolve - including cases signed today. |
| Failure to Warn | Plaintiffs allege Pfizer knew or should have known of the risk and failed to warn U.S. patients for decades, while warnings appeared earlier in other markets. European regulators had already required meningioma warnings for high-dose medroxyprogesterone products. |
Qualifying Criteria for Law Firms
How We Qualify & Sort Every Depo Provera Lead
The qualifying bar in Depo-Provera is high - and that's good. A confirmed brain-tumor diagnosis filters out most inquiries before they reach intake. We screen for the facts that actually determine whether a case survives defense scrutiny.
| Screening Step | What We Verify |
|---|---|
| Brand-Name Exposure | Confirmed use of Pfizer-branded Depo-Provera or Depo-subQ Provera. Because liability runs to the brand, we screen out unconfirmed generic-only use that weakens causation. |
| Duration Threshold | Minimum of roughly one year of use - about four injections - aligned with the risk cohort in the published studies. We capture the full injection history rather than a yes/no, because the JAMA Neurology cohort concentrated risk above four years of exposure and your criteria sheet may want to go tighter than the floor. Single-shot inquiries are rejected at the funnel. |
| Imaging-Confirmed Meningioma | A diagnosed intracranial or spinal meningioma confirmed by MRI or CT - not headaches, not "symptoms." We exclude unrelated conditions such as glioblastoma or migraine without a tumor. |
| Timing Correlation | Use-duration mapped against diagnosis date to support causation and position the claim against the applicable statute of limitations. |
| Records Pathway Check | Because some exposure dates back decades, we flag record accessibility - pharmacy, physician, and insurer - before delivery, so your intake team isn't chasing 20-year-old records blind. |
| Compliance & Consent | TCPA consent documented with TrustedForm/Jornaya, identity and fraud screening on every contact, and HIPAA-aware intake throughout. |
What Disqualifies a Depo Provera Lead
Screening is defined as much by what we reject as by what we pass. These are rejected at the funnel rather than delivered and argued about later:
- Symptoms without a diagnosis. Headaches, vision changes or dizziness with no imaging are not meningioma claims, however motivated the caller.
- A different tumour. Glioblastoma, pituitary adenoma and acoustic neuroma are excluded; the claim is meningioma-specific.
- Unconfirmed generic-only exposure. Liability runs to brand-name Depo-Provera and Depo-subQ Provera, so generic-only histories we cannot substantiate are screened out.
- Short exposure. One or two injections falls below the published risk cohort entirely.
- Expired statute of limitations. Mapped per state against the diagnosis date, not the injection date.
- Prior representation. Claimants already signed with another firm never reach your intake desk.
- Failed identity or fraud screening. Every contact is risk-scored and identity-matched before a human picks up.
Marketing Solutions
Every Channel.
One Platform.
We are proud to offer a wide range of marketing options. Our services are fully customizable and tailored to your firm's needs.
Exclusive Web Leads
Inbound web leads generated for your firm alone — never resold or shared
Exclusive Live Transfers
Pre-screened claimants transferred live to your staff, ready to retain
Signed Retainers
Fully executed retainer agreements delivered - skip intake entirely
Integrations
We Connect With the Industry's
Leading Case Management Systems.
With just under a decade and a half of experience, our work has pushed the boundaries of Legal Marketing. We seamlessly plug into the tools your firm already uses - delivering claimants directly into your existing workflow.
Federal Track or State Track
Where Your Depo Provera Cases Actually Get Filed
Not every Depo-Provera claimant belongs in MDL 3140. Venue changes the timetable, the settlement posture and sometimes the statute of limitations - so we sort every lead to a track before delivery rather than handing you an undifferentiated list. The MDL has held joint case management conferences with the New York and Delaware courts, which is why coordination between tracks matters more in this tort than most.
Federal — MDL 3140
Master Docket 3:25-md-3140 in Pensacola, with Magistrate Judge Hope T. Cannon. Christopher Seeger of Seeger Weiss serves as Plaintiffs' Lead Counsel, with Bryan Aylstock and Ellen Relkin as Co-Leads. 6,413 actions pending per the November 2026 JPML report.
Delaware State Court
An active consolidated state docket that has sat in joint case management conferences with the federal MDL. Pfizer's corporate domicile makes Delaware a durable venue for this litigation.
New York State Court
A coordinated New York docket, also represented at joint CMCs with the MDL and the Delaware court. Relevant for claimants whose treatment and injection records sit in-state.
California, Minnesota & Others
Further state-court activity continues alongside the federal docket. We filter inventory by the states your firm is licensed and willing to file in, so you are never sold a claimant you cannot actually serve.
What Arrives With Every Lead
The Documentation That Decides a Depo Provera Case
With allocation criteria unpublished and a Rule 702 ruling pending, documentation is the difference between an asset and a liability on your docket. Depo-Provera is unusually hard here: exposure often dates back fifteen or twenty years, and because the drug is administered rather than dispensed over a counter, claimants frequently cannot produce their own injection history.
That is a screening problem, not an intake problem, and we treat it as one. Every delivered claimant arrives with the file below attached and retrievable years later - not a name and a phone number for your paralegals to reconstruct.
If you would rather we execute the retainer as well, that is our mass tort case acquisition service; the document set is the same, with the signed agreement on top.
- Brand verification. Confirmation of Depo-Provera or Depo-subQ Provera rather than an unsubstantiated generic history.
- Injection history. Approximate count, date range and administering provider, with a records-accessibility flag where the exposure is decades old.
- Imaging confirmation. MRI or CT confirming an intracranial or spinal meningioma, with diagnosis date captured.
- Treatment profile. Surgical, radiation or monitored - the single largest driver of case value in this tort.
- HIPAA authorisation. Executed at intake so your team can pull records without a second contact.
- Statute-of-limitations mapping. Diagnosis date checked against the applicable state deadline before delivery.
- TCPA consent trail. Form language, timestamp, IP address, page URL and call recording, with TrustedForm or Jornaya certification.
- Identity verification. SSN, address and date-of-birth matching plus fraud screening on every contact.
Why Choose Injury Case Claims
Why Firms Source Depo Provera Leads From Us
We've delivered 133,000 leads to law firms since 2009 - fifteen-plus years of campaign data across every major MDL of that period. That same screening discipline now powers our Depo Provera lead generation, because in this tort documentation quality, not raw volume, decides whether a case holds up.
Choose the Model That Fits Your Capacity
Depo Provera Lead Types
Whether you call them Depo Provera lawsuit leads, meningioma leads or simply claimants, the test is the same - can your intake team turn them into signed cases? Every model can be filtered by geography, meningioma grade, surgical vs. monitored profile and documentation depth, so the inventory matches your litigation strategy and your statute-of-limitations map.
| Lead Type | Best For |
|---|---|
| Exclusive Depo Provera Leads | Sold to your firm only and never resold or shared. You're the only call the claimant expects, with full ownership of the relationship. Delivered in real time to your CRM the moment they clear identity verification. |
| Depo Provera Signed Retainers | Fully executed retainer agreements on your paper, plus HIPAA authorisations and a QC review, delivered case-ready to your CRM (Filevine, Litify and others) through our automation layer rather than rekeyed by hand. Priced per signed case. Full detail on our mass tort case acquisition page. |
| Qualified-Lead Packages | Pre-screened, high-intent meningioma claimants for firms that run their own intake and want to control the final sign step. Available as real-time web leads or live call transfers where intake speed decides conversion. |
What This Tort Costs - Straight Talk
Depo Provera Lead Costs & Why the Economics Still Work
We won't pretend Depo-Provera is cheap. Firms researching Depo Provera lead cost deserve real numbers, not vague promises - and the published benchmarks tell a clear story about why the math holds. One caveat before the table: cost per lead and cost per signed case are different products at similar-looking prices, and cost per qualified lead is the only figure worth comparing between vendors.
| Market Signal | What It Means for Your Firm |
|---|---|
| Cost Per Signed Case ≈ $5,000+ | Published industry benchmarks put cost-per-signed-retainer among the highest of any active tort - figures around $5,000+ per signed case. The reason is the qualifying bar itself: a confirmed brain-tumor diagnosis filters out most inquiries. |
| The Screening Is a Feature | That high bar is why the economics work. A single qualified surgical case carries projected value many multiples above acquisition cost. Settlement terms aren't public, so any case-value figures are third-party estimates, not guarantees. |
| Priced to Your Criteria | We price by lead type, documentation depth, exclusivity, and geography - so you know exactly what you're paying for before the first lead arrives, rather than a flat rate regardless of how loosely "qualified" is defined. |
| The Window Rewards Documentation | With the Master Settlement Agreement signed and allocation criteria unpublished, eligibility for newly-signed cases will only get more contested. Documentation quality is now the whole game - which is precisely what our intake is built to deliver. |
Full Compliance
Depo Provera Lead Compliance: Built on Industry Standards
Operating since 2009, we've developed processes that ensure potential leads are treated fairly and their privacy respected. In a medical-record-driven tort like Depo-Provera, that care matters more than ever. We achieve full compliance with TCPA, HIPAA, ABA, and federal and state statutes.
What Firms Say About Our
Mass Tort Leads
Partners who have run mass tort campaigns with us, in their own words.
Injury Case Claims have consistently exceeded our expectations with the highest quality of service and quality of case leads we have seen in a long time. It is my opinion and experience that quality is not cheap, it is PRICELESS when you build your docket.
The team at ICC have an eye for details that even my own paralegals have not established. To work with an all-in-one company is a blessing in disguise because their pro plan has unlocked a ton of time for my staff and myself. The money is well worth the transparency and added value in services received.
We have been doing mass torts for 21 years and have worked with quite a few marketing companies, but when we got onboard with Injury Case Claims we knew this was going to be a different experience from day one. They truly offer excellent communications throughout each step of the onboarding process, with quality of cases superb.
I have worked with Injury Case Claims on several campaigns for which my experience has been nothing short of great. Thanks and keep up the good work so we can be partners for many years to come.
Get Started
Request Your Depo Provera Leads
Inventory & Pricing
If your firm is looking for authentic legal marketing for case leads for your Depo-Provera, mass tort, or Personal Injury docket, give us the opportunity to earn your business.
We promise the best quality with the industry's best return policy. No other company offers investment protection like we do.
Real-Time Leads
Instant updates so you never miss an opportunity.
Qualified Cases
Every lead is pre-screened and ready to convert.
Maximum Results
Our technology connects you with high-value cases.
Secure & Reliable
Your data and leads are always protected.
Experience Matters
EST. 2009 ★★★★★
FAQ
Depo Provera Leads - Frequently Asked Questions
Straight answers to what firms ask before buying Depo Provera leads or launching a first campaign with Injury Case Claims. Anything not covered here, call and ask.